Hylan G-F 20
Intra-articular treatment for osteoarthritis of the knee in patients who have not responded to non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroid injections, or are unable to take NSAIDs or receive corticosteroid injections for safety reasons.
Access path
- Mar 2006Not recommended
uncertain clinical benefit, uncertain and unacceptable cost-effectiveness, observer bias in pragmatic trial, small and…
- Mar 2006Not recommended
uncertain clinical benefit, uncertain and unacceptable cost-effectiveness, observer bias in pragmatic trial, small and…
Cost-effectiveness
Base case modelled incremental cost per extra QALY; PBAC considered these ratios uncertain due to observer bias concerns
Given the issues raised concerning observer bias with the trial, the PBAC considered the incremental cost-effectiveness ratios to be uncertain. PBAC · 2006
Decision context
PopulationPatients with osteoarthritis of the knee who have not responded to NSAIDs or corticosteroid injections, or are unable to take NSAIDs or receive corticosteroid injections for safety reasons.
Why it was knocked back
- uncertain clinical benefit, uncertain and unacceptable cost-effectiveness, observer bias in pragmatic trial, small and clinically doubtful benefit, lack of data on more important outcomes such as ability to exercise or activities of daily living, uncertainty over predicted usage, concerns about restriction enforcement
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2006 | Not recommended | all standard non-pharmacological and pharmacological therapies including NSAIDs and corticosteroid injections | $15k–45k | RCT · pain on weight bearing (WOMAC assessment scale) |
| Mar 2006 | Not recommended | standard non-pharmacological and pharmacological therapies including NSAIDs and corticosteroid injections | $15k–45k | RCT |